RGD Reference Report - Carcinogenesis of pancreatic adenocarcinoma: precursor lesions. - Rat Genome Database

Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

Carcinogenesis of pancreatic adenocarcinoma: precursor lesions.

Authors: Gnoni, A  Licchetta, A  Scarpa, A  Azzariti, A  Brunetti, AE  Simone, G  Nardulli, P  Santini, D  Aieta, M  Delcuratolo, S  Silvestris, N 
Citation: Gnoni A, etal., Int J Mol Sci. 2013 Sep 30;14(10):19731-62. doi: 10.3390/ijms141019731.
RGD ID: 8694139
Pubmed: PMID:24084722   (View Abstract at PubMed)
PMCID: PMC3821583   (View Article at PubMed Central)
DOI: DOI:10.3390/ijms141019731   (Journal Full-text)

Pancreatic adenocarcinoma displays a variety of molecular changes that evolve exponentially with time and lead cancer cells not only to survive, but also to invade the surrounding tissues and metastasise to distant sites. These changes include: genetic alterations in oncogenes and cancer suppressor genes; changes in the cell cycle and pathways leading to apoptosis; and also changes in epithelial to mesenchymal transition. The most common alterations involve the epidermal growth factor receptor (EGFR) gene, the HER2 gene, and the K-ras gene. In particular, the loss of function of tumor-suppressor genes has been documented in this tumor, especially in CDKN2a, p53, DPC4 and BRCA2 genes. However, other molecular events involved in pancreatic adenocarcinoma pathogenesis contribute to its development and maintenance, specifically epigenetic events. In fact, key tumor suppressors that are well established to play a role in pancreatic adenocarcinoma may be altered through hypermethylation, and oncogenes can be upregulated secondary to permissive histone modifications. Indeed, factors involved in tumor invasiveness can be aberrantly expressed through dysregulated microRNAs. This review summarizes current knowledge of pancreatic carcinogenesis from its initiation within a normal cell until the time that it has disseminated to distant organs. In this scenario, highlighting these molecular alterations could provide new clinical tools for early diagnosis and new effective therapies for this malignancy.


Additional Information